Skip to main content
DNTH logo

DNTH · Dianthus Therapeutics, Inc. /DE/ · Webcasts, Transcripts & Audio

Track DNTH — free
$88.90 +0.85 (+0.97%)
Market Cap
$5.23B
Shares
55.93M
Volume · Oct 1 767.07K Avg daily vol (3M) 833.35K

Dianthus Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Dianthus Therapeutics, Inc. (DNTH), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-09-10
Dianthus Therapeutics, Inc. (DNTH) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-09
Dianthus Therapeutics, Inc. (DNTH) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-09
Dianthus Therapeutics, Inc. (DNTH) Q4 2025 Earnings Call Transcript
Confident tone Clasipabart efficacy and differentiation vs. relipobart Broader neuromuscular pipeline Part B trial design optimization
Revenue
$284,000*
▼ 78.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q2
2022-08-04
Dianthus Therapeutics, Inc. (DNTH) Q2 2022 Earnings Call
Diluted EPS
$-0.29
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Dianthus Therapeutics, Inc. (DNTH) Q4 2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q4
2021-01-11
Dianthus Therapeutics, Inc. (DNTH) Q4 2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q1
2020-05-07
Dianthus Therapeutics, Inc. (DNTH) Q1 2020 Earnings Call
Revenue
$
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Dianthus Therapeutics, Inc. (DNTH) Q4 2019 Earnings Call
Revenue
$
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–8 of 8 webcasts
Key facts CIK 1690585 CUSIP 252828108 13F (30d) 8 filings 8 filers Visit website Investor relations